Quarterly ResultMay 7, 2026, 09:07 AM
Lipocine Q1 Net Loss Widens to $3.67M; EPS $(0.54)
AI Summary
Lipocine Inc. reported a significant increase in net loss for the first quarter of 2026, reaching $3.67 million, up from $1.86 million in the same period last year. This was primarily driven by a substantial rise in research and development expenses. The company also raised $12.0 million in net proceeds through an At-The-Market common stock offering during the quarter, which contributed to an increase in total stockholders' equity and marketable investment securities, despite a slight decrease in cash and cash equivalents. Lipocine stated that its existing capital resources are sufficient through at least May 7, 2027, but additional capital will be needed for long-term operations.
Key Highlights
- Net loss for Q1 2026 widened to $3.67 million from $1.86 million in Q1 2025.
- Basic loss per share was $(0.54) for Q1 2026, compared to $(0.35) in Q1 2025.
- Total revenues increased to $119,397 in Q1 2026 from $93,864 in Q1 2025.
- Research and development expenses significantly increased to $2.76 million from $1.06 million year-over-year.
- Net proceeds from the At-The-Market (ATM) offering were $12.0 million from 1.31 million shares.
- Cash and cash equivalents were $5.02 million as of March 31, 2026.
- Marketable investment securities increased to $19.71 million as of March 31, 2026, from $9.72 million at December 31, 2025.
- Total stockholders' equity rose to $22.83 million as of March 31, 2026, from $14.48 million at December 31, 2025.